Medical treatment of osteoarthritis in the horse - A review

被引:178
作者
Goodrich, LR [1 ]
Nixon, AJ [1 ]
机构
[1] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA
关键词
osteoarthritis; medical treatment; nonsteroidal anti-inflammatory drugs; hyaluronan; glucosamine/chondroitin sulphate;
D O I
10.1016/j.tvjl.2004.07.008
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 [兽医学];
摘要
The medical treatment of osteoarthritis (OA) in the horse is one of the most utilized therapeutic regimens in the equine practice. It is important to understand the anatomy of synovial joints and the pathophysiology of the disease process to treat OA adequately. Once a thorough understanding of the disease process is comprehended the proper combination of systemic nonsteroidal anti-inflammatory drugs (NSAIDs), intraarticular steroids, viscosupplementation and chondroprotectants can be used to treat the disease and inhibit further progression of degenerative changes to the cartilage surface. The equine practitioner is faced with many choices for controlling inflammation in OA. This review presents the background and appropriate uses of various NSAIDs such as phenylbutazone, flunixin meglumine, ketoprofen, naproxen, and carprofen as well as their associated toxicities. Various steroid formulations exist for intraarticular (IA) administration and much has been learned in the past decade regarding correct dosage, frequency of administrations, indications and toxicity. This review presents IA steroids and their indications in addition to various chondroprotective drugs that also exist to control inflammation and provide viscosupplementation. Data are also given on disease modifying OA drugs such as glucosamine and chondroitin sulphate that have more recently become available to the equine practitioner. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:51 / 69
页数:19
相关论文
共 171 条
[1]
The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs [J].
Adebowale, A ;
Du, JP ;
Liang, ZM ;
Leslie, JL ;
Eddington, ND .
BIOPHARMACEUTICS & DRUG DISPOSITION, 2002, 23 (06) :217-225
[2]
Adebowale A. O., 2000, JANA, V3, P37
[3]
Molecular pathology and pathobiology of osteoarthritic cartilage [J].
Aigner, T ;
McKenna, L .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2002, 59 (01) :5-18
[4]
ANDREWS JL, 1985, ARZNEIMITTELFORSCH, V35, P144
[5]
VARIATIONS IN THE INTRINSIC MECHANICAL PROTERTIES OF HUMAN ARTICULAR-CARTILAGE WITH AGE, DEGENERATION, AND WATER-CONTENT [J].
ARMSTRONG, CG ;
MOW, VC .
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1982, 64 (01) :88-94
[6]
Pharmacokinetics of carprofen enantiomers in equine plasma and synovial fluid - a comparison with ketoprofen [J].
Armstrong, S ;
Tricklebank, P ;
Lake, A ;
Frean, S ;
Lees, P .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1999, 22 (03) :196-201
[7]
Armstrong S, 1999, AM J VET RES, V60, P98
[8]
Human osteoarthritic cartilage exhibits the 2B6 epitope without pretreatment with chondroitinase ABC [J].
Asari, A ;
Akizuki, S ;
Itoh, T ;
Kominami, E ;
Uchiyama, Y .
OSTEOARTHRITIS AND CARTILAGE, 1996, 4 (02) :149-152
[9]
AVIAD AD, 1994, J RHEUMATOL, V21, P297
[10]
Axelrod L, 1993, TXB RHEUMATOLOGY, P779